Soluble Interleukin-6 Receptor is a Prognostic Marker for Relapse-Free Survival in Estrogen Receptor-Positive Breast Cancer
| Autor: | Eun Kyoung Jeon, Der Sheng Sun, Jun Sang Lee, Hye Sung Won, Young Ae Kim, Jeong Soo Kim, Yoon Ho Ko, Ho Jung An |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Soluble Glycoprotein 130 medicine.drug_class Estrogen receptor Breast Neoplasms Disease-Free Survival Breast cancer Internal medicine Biomarkers Tumor Cytokine Receptor gp130 Humans Medicine Interleukin 6 Receptor Aged Neoplasm Staging Aged 80 and over biology Interleukin-6 business.industry Cancer General Medicine Middle Aged medicine.disease Receptors Interleukin-6 Soluble Interleukin 6 Receptor Receptors Estrogen Estrogen biology.protein Female Neoplasm Recurrence Local business |
| Zdroj: | Cancer Investigation. 31:516-521 |
| ISSN: | 1532-4192 0735-7907 |
| DOI: | 10.3109/07357907.2013.826239 |
| Popis: | Considering the protumorigenic roles of interleukin-6 (IL-6) transsignaling, we assessed the serum levels of IL-6, soluble interleukin-6 receptor (sIL-6R), and soluble glycoprotein 130 (sgp130) in 143 patients with breast cancer. Serum levels of IL-6 were elevated with advanced T and N stage. Serum levels of sIL-6R were lower in patients with estrogen receptor-positive cancer. The median values of IL-6 and sgp130 did not differ between patients with recurrence and those without recurrence. However, higher serum levels of sIL-6R at diagnosis were associated with significantly shorter relapse-free survival in patients with estrogen receptor-positive breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |